Literature DB >> 22623208

Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children's oncology group.

Alena Y Z Edwards1, Jeffrey M Skolnik, Erin Dombrowsky, Dimple Patel, Jeffrey S Barrett.   

Abstract

BACKGROUND: The binding of drugs to catheters can be a source variation in dosing chemotherapeutics. Drug contamination from the dosing central venous line (CVL) can impact the reporting of pharmacokinetic (PK) results and analysis. Peripheral venipuncture avoids binding complications from the CVL but dissuades patients from enrolling. Our group has developed a catheter clearing procedure to minimize the extent of contamination so that dosing and sampling from the CVL can ensue, promoting patient willingness to participate in phase I pediatric oncology trials.
OBJECTIVES: To develop a population pharmacokinetic model of actinomycin-D (AMD) in children with cancer incorporating expressions for drug contamination from PK samples obtained via indwelling CVLs and to evaluate the efficiency of a catheter clearing procedure in removing contamination as well as the impact of contamination on PK results.
METHODS: A dataset of 199 AMD plasma concentration measurements from 36 patients (age 1.6-20.3 years) was analyzed using nonlinear mixed-effects modeling. Quantitative modeling approaches, including baseline contamination model, covariate model, and catheter clearance model, were evaluated to describe catheter contamination. Monte Carlo simulations mimicking a prospective study in children with cancer were performed to assess the performance of the final model and impact of catheter contamination on PK reporting.
RESULTS: The PK of AMD was best described by a linear 3-compartment model with first-order elimination. A baseline contamination model including a contamination factor proportional to the model-predicted concentration for samples obtained from central catheters was chosen as the most parsimonious and accurate among competing models. The final model parameters were allometrically scaled to a 70 kg person. The estimated mean parameter values were 11 L/h, 5.79, 24.2, 490 L, 17.7, and 42.8 L/h for total clearance, central volume of distribution, peripheral volume 1, peripheral volume 2, inter-compartmental clearance 1, and inter-compartmental clearance 2, respectively. The proportional contamination factor was 19.3 % immediately post-drug administration and decreased at a first-order rate of 0.0932 h(-1). Simulations precisely re-estimated kinetic parameters with catheter contamination adjustment. Large uncertainty and poor estimation were observed when contamination was ignored.
CONCLUSIONS: Drug contamination from sampling catheter can impact AMD PK results and should be accounted for in the analysis. We provide a framework for evaluating catheter contamination and guidance on adjustment in the PK model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623208      PMCID: PMC4008333          DOI: 10.1007/s00280-012-1878-y

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels.

Authors:  Milly E de Jonge; Ron A A Mathôt; Selma M van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Ther Drug Monit       Date:  2003-06       Impact factor: 3.681

2.  Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.

Authors:  Gareth J Veal; Michael Cole; Julie Errington; Annie Parry; Juliet Hale; Andrew D J Pearson; Karen Howe; Julia C Chisholm; Carol Beane; Bernadette Brennan; Fiona Waters; Adam Glaser; Sue Hemsworth; Heather McDowell; Yvonne Wright; Kathy Pritchard-Jones; Ross Pinkerton; Gail Jenner; James Nicholson; Ann M Elsworth; Alan V Boddy
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

3.  Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.

Authors:  Bryan Langholz; Jeffrey M Skolnik; Jeffrey S Barrett; Jamie Renbarger; Nita L Seibel; Anne Zajicek; Carola A S Arndt
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

4.  A size standard for pharmacokinetics.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

5.  Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer.

Authors:  Jeffrey M Skolnik; Alena Y Zhang; Jeffrey S Barrett; Peter C Adamson
Journal:  Ther Drug Monit       Date:  2010-12       Impact factor: 3.681

6.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Authors:  Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

7.  Population pharmacokinetic investigation of actinomycin-D in children and young adults.

Authors:  John T Mondick; Leonid Gibiansky; Marc R Gastonguay; Jeffrey M Skolnik; Michael Cole; Gareth J Veal; Alan V Boddy; Peter C Adamson; Jeffrey S Barrett
Journal:  J Clin Pharmacol       Date:  2008-01       Impact factor: 3.126

8.  Central venous catheters versus peripheral veins for sampling blood levels of commonly used drugs.

Authors:  R J Shulman; C Ou; T Reed; P Gardner
Journal:  JPEN J Parenter Enteral Nutr       Date:  1998 Jul-Aug       Impact factor: 4.016

9.  Therapeutic monitoring of cyclosporine following pediatric bone marrow transplantation: problems with sampling from silicone central venous lines.

Authors:  C L Leson; S M Bryson; E E Giesbrecht; E F Saunders
Journal:  DICP       Date:  1989-04
  9 in total
  3 in total

Review 1.  Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

Authors:  Johan G C van Hasselt; Natasha K A van Eijkelenburg; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

2.  Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.

Authors:  Christopher R Hill; Michael Cole; Julie Errington; Ghada Malik; Alan V Boddy; Gareth J Veal
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

3.  Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1.

Authors:  Jeffrey Skolnik; David Hall; Donald A Barkauskas; Ganesh Moorthy; Thomas R Larson; Elizabeth Fox; Brenda J Weigel; Stacey L Berg; Joel M Reid
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-22       Impact factor: 3.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.